Published in Onkologie on February 22, 2010
Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med (2011) 27.58
Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med (2012) 20.79
Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med (2012) 15.69
Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med (2014) 11.05
Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet (2011) 8.81
Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol (2013) 4.91
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer (2012) 4.29
Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. Lancet Oncol (2013) 3.45
Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer. Eur Urol (2008) 3.06
Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol (2013) 2.52
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol (2007) 2.21
Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure. J Bone Miner Res (2010) 2.15
Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials. Clin Cancer Res (2013) 2.06
High-risk prostate cancer: from definition to contemporary management. Eur Urol (2012) 2.06
EAU guidelines on testicular cancer: 2011 update. Eur Urol (2011) 1.96
Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol (2009) 1.83
Active surveillance is the preferred approach to clinical stage I testicular cancer. J Clin Oncol (2013) 1.81
Targeting continued androgen receptor signaling in prostate cancer. Clin Cancer Res (2011) 1.80
Functional outcomes and complications following radiation therapy for prostate cancer: a critical analysis of the literature. Eur Urol (2011) 1.80
Carcinoma of unknown primary (CUP). Crit Rev Oncol Hematol (2008) 1.65
Cancer of unknown primary (CUP). Crit Rev Oncol Hematol (2005) 1.53
Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. Lancet Oncol (2013) 1.51
Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities? J Clin Oncol (2011) 1.48
Guidelines for target volume definition in post-operative radiotherapy for prostate cancer, on behalf of the EORTC Radiation Oncology Group. Radiother Oncol (2007) 1.44
Testicular-sparing surgery for bilateral or monorchide testicular tumours: a multicenter study of long-term oncological and functional results. BJU Int (2014) 1.44
Enzalutamide in European and North American men participating in the AFFIRM trial. BJU Int (2014) 1.43
Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. J Clin Oncol (2002) 1.40
Identifying the primary site using gene expression profiling in patients with carcinoma of an unknown primary (CUP): a feasibility study from the GEFCAPI. Onkologie (2012) 1.39
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur Urol (2007) 1.37
Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study--trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). J Clin Oncol (2003) 1.30
Targeting a cornerstone of radiation resistance: cancer stem cell. Cancer Lett (2012) 1.24
[Standards, Options and Recommendations for the management of patient with carcinoma of unknown primary site]. Bull Cancer (2002) 1.24
Sequential therapy in renal cell carcinoma. Cancer (2009) 1.18
Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone. Cancer (2012) 1.16
Guidelines for primary radiotherapy of patients with prostate cancer. Radiother Oncol (2006) 1.15
Tumor assessment criteria in phase I trials: beyond RECIST. J Clin Oncol (2012) 1.15
Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer. Urology (2011) 1.15
Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone. Clin Cancer Res (2012) 1.13
Replanning during intensity modulated radiation therapy improved quality of life in patients with nasopharyngeal carcinoma: in regard to Yang et al. Int J Radiat Oncol Biol Phys (2013) 1.13
Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies. Cancer (2013) 1.13
Implications of prostate-specific antigen doubling time as indicator of failure after surgery or radiation therapy for prostate cancer. Eur Urol (2006) 1.10
Long-term results of brachytherapy for carcinoma of the penis confined to the glans (N- or NX). Int J Radiat Oncol Biol Phys (2009) 1.07
Controversies in the management of clinical stage I testis cancer. J Clin Oncol (2006) 1.05
Chemotherapy in patients with teratoma with malignant transformation. Eur Urol (2006) 1.03
Treatment for patients with unknown primary cancer and favorable prognostic factors. Semin Oncol (2009) 1.03
Targeting head and neck cancer stem cells to overcome resistance to photon and carbon ion radiation. Stem Cell Rev (2014) 1.01
Carcinomas of an unknown primary origin--diagnosis and treatment. Nat Rev Clin Oncol (2011) 1.00
Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy. Eur J Cancer (2013) 0.98
Efficacy of re-challenging metastatic renal cell carcinoma with mTOR inhibitors. Acta Oncol (2011) 0.95
New and emerging therapies for bone metastases in genitourinary cancers. Eur Urol (2012) 0.95
The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer. Eur J Cancer (2010) 0.94
Overcoming resistance to tyrosine kinase inhibitors in renal cell carcinoma. Cancer Treat Rev (2012) 0.94
STEAP, a prostate tumor antigen, is a target of human CD8+ T cells. Cancer Immunol Immunother (2006) 0.93
Intra-abdominal desmoplastic small round cell tumors: CT findings and clinicopathological correlations in 13 cases. Eur J Radiol (2005) 0.93
Uterine and ovary carcinosarcomas: outcome, prognosis factors, and adjuvant therapy. Am J Clin Oncol (2015) 0.93
Optimizing treatment for men with advanced prostate cancer: expert recommendations and the multidisciplinary approach. Crit Rev Oncol Hematol (2008) 0.93
The MTHFR 677C > T polymorphism is associated with an increased risk of hepatocellular carcinoma in patients with alcoholic cirrhosis. Carcinogenesis (2004) 0.92
Second line treatment of metastatic renal cell carcinoma: The Institut Gustave Roussy experience with targeted therapies in 251 consecutive patients. Eur J Cancer (2013) 0.90
External beam accelerated partial-breast irradiation using 32 gy in 8 twice-daily fractions: 5-year results of a prospective study. Int J Radiat Oncol Biol Phys (2012) 0.89
Combination of topotecan and oxaliplatin in inoperable hepatocellular cancer patients. Am J Clin Oncol (2002) 0.87
Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart review. Int J Oncol (2013) 0.87
A 10-year clinical experience with intermittent hormonal therapy for prostate cancer. Eur Urol (2003) 0.87
Stemness markers characterize IGR-CaP1, a new cell line derived from primary epithelial prostate cancer. Exp Cell Res (2010) 0.86
Patient preference for either the EORTC QLQ-C30 or the FACIT Quality Of Life (QOL) measures: a study performed in patients suffering from carcinoma of an unknown primary site (CUP). Eur J Cancer (2004) 0.86
Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study. Invest New Drugs (2014) 0.86
The use of estramustine phosphate in the modern management of advanced prostate cancer. BJU Int (2011) 0.85
Bone targeted therapies in metastatic castration-resistant prostate cancer. Cancer J (2013) 0.85
Accelerated MVAC chemotherapy in patients with advanced bladder cancer previously treated with a platinum-gemcitabine regimen. Eur J Cancer (2012) 0.85
Nonseminomatous germ cell tumors: assessing the need for postchemotherapy contralateral pulmonary resection in patients with ipsilateral complete necrosis. J Thorac Cardiovasc Surg (2009) 0.84
The IGR-CaP1 xenograft model recapitulates mixed osteolytic/blastic bone lesions observed in metastatic prostate cancer. Neoplasia (2012) 0.83
Targeting CDC25C, PLK1 and CHEK1 to overcome Docetaxel resistance induced by loss of LZTS1 in prostate cancer. Oncotarget (2014) 0.83
Reappraisal of clinical outcome in adult medulloblastomas with emphasis on patterns of relapse. Br J Neurosurg (2010) 0.83
Whole brain radiotherapy: prognostic factors and results of a radiation boost delivered through a conventional linear accelerator. Radiother Oncol (2011) 0.83
Curative-intended treatment of squamous cell anal carcinoma in elderly adults. J Am Geriatr Soc (2012) 0.83
Salvage radiotherapy: a plea for dose-escalation with intensity-modulated radiotherapy. Eur J Cancer (2012) 0.82
Nomograms to predict late urinary toxicity after prostate cancer radiotherapy. World J Urol (2013) 0.82
Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy. Cancer Immunol Immunother (2015) 0.82
Combination therapy in metastatic renal cell cancer. Semin Oncol (2013) 0.81
Emerging antiangiogenics for renal cancer. Expert Opin Emerg Drugs (2013) 0.81
Pharmacological strategies to spare normal tissues from radiation damage: useless or overlooked therapeutics? Cancer Metastasis Rev (2012) 0.81
Investigation in liver tissues and cell lines of the transcription of 13 genes mapping to the 16q24 region that are frequently deleted in hepatocellular carcinoma. Clin Cancer Res (2002) 0.81
Advanced seminoma and nonseminoma: SIU/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009. Urology (2011) 0.80
Taxanes: still a major weapon in the armamentarium against prostate cancer. Eur Urol (2013) 0.80
Sunitinib inducing tumor lysis syndrome in a patient treated for renal carcinoma. Invest New Drugs (2009) 0.80
Gemcitabine-oxaliplatin combination in heavily pretreated metastatic breast cancer: a pilot study on 43 patients. Breast J (2007) 0.79
IGF1R gene expression as a predictive marker of response to ionizing radiation for patients with locally advanced HPV16-positive cervical cancer. Anticancer Res (2012) 0.79
Surgical outcomes in patients with primary mediastinal non-seminomatous germ cell tumours and elevated post-chemotherapy serum tumour markers. Eur J Cardiothorac Surg (2012) 0.79
Microsatellite instability mutator phenotype in hepatocellular carcinoma in non-alcoholic and non-virally infected normal livers. Carcinogenesis (2003) 0.79
Protein kinase inhibitors in renal cell carcinoma. Expert Opin Pharmacother (2013) 0.78
Reflex sympathetic dystrophy in patients with metastatic renal cell carcinoma treated with everolimus. Invest New Drugs (2009) 0.78